Objective: Time in therapeutic range (TTR) is a new approach to monitoring blood pressure (BP), providing a more accurate picture over time compared to the standard single BP measurement during a clinic visit. Currently, no study from Saudi Arabia has explored the use of TTR in assessing BP control and its related factors. Thus, we aimed to investigate them in this study.
Patients And Methods: Participants aged ≥ 18 years with at least three BP measurements from January 2016 to December 2020 were enrolled. Patient data were collected, including the date of hypertension (HTN) diagnosis, comorbidities, medication history, and laboratory test results. TTR values were calculated, and descriptive statistical analysis was applied to assess the differences between patients with TTR ≥ 50% and those with TTR < 50%. The Poisson regression model was used to describe the associations between patient characteristics and TTR values.
Results: 30,694 patients were included, with 74% identified as having TTR < 50%. Female gender, concomitant diabetes mellitus, or cardiovascular diseases were significantly associated with TTR ≥ 50% (p < 0.02). Conversely, increasing age, body mass index, years with HTN, or hyperlipidemia were associated with TTR < 50% (p < 0.001).
Conclusions: According to the 2017 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines, about three-quarters of the patients presented with TTR < 50% among the screened Saudi cohort. The results of this study may raise concerns about clinicians' adherence to the updated HTN management guidelines and patients' compliance with their treatment plans. This underscores the urgent need to improve HTN management and TTR attainment among Saudi patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.26355/eurrev_202412_36976 | DOI Listing |
J Clin Med
December 2024
Pfizer S.L.U., 28108 Madrid, Spain.
Hereditary transthyretin amyloidosis (ATTRv) is an autosomal-dominant systemic disease, where amyloid fibrils accumulate especially in the peripheral and autonomic nervous systems and in the heart. The aim of the present work was to outline the follow-up and type of management received by asymptomatic carriers (ACs) and stage 1 ATTRv patients in Spain. A cross-sectional, non-interventional study was conducted throughout seven experienced hospitals in Spain.
View Article and Find Full Text PDFBMC Med
December 2024
Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology & Population Health, London, School of Hygiene and Tropical Medicine, London, UK.
Background: Direct oral anticoagulants (DOACs) have been reported to be associated with a higher risk of mortality compared with an older alternative, warfarin using primary care data in the United Kingdom (UK). However, other studies observed contradictory findings. We therefore aimed to investigate the association between mortality and warfarin, compared with DOACs.
View Article and Find Full Text PDFJ Clin Oncol
December 2024
Department of Dermatology, The University of Texas-MD Anderson Cancer Center, Houston, TX.
Purpose: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL).
Patients And Methods: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles.
Genet Med
December 2024
The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:
Purpose: Previous studies have established "red flags" that raise clinical suspicion for the hereditary form of transthyretin amyloidosis (ATTRv). However, these have not been specifically evaluated for the most common associated variant, TTR p.(Val142Ile).
View Article and Find Full Text PDFEur Rev Med Pharmacol Sci
December 2024
Pharmaceutical Analysis Department, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
Objective: Time in therapeutic range (TTR) is a new approach to monitoring blood pressure (BP), providing a more accurate picture over time compared to the standard single BP measurement during a clinic visit. Currently, no study from Saudi Arabia has explored the use of TTR in assessing BP control and its related factors. Thus, we aimed to investigate them in this study.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!